The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.
 
Maryann J. Kwa
No Relationships to Disclose
 
Alyssa Iwano
No Relationships to Disclose
 
Francisco J. Esteva
Consulting or Advisory Role - Celgene; Celltrion; Genentech/Roche; NanoString Technologies; Novartis; Spectrum Pharmaceuticals
Research Funding - Kadmon (Inst); Merrimack (Inst); Novartis (Inst); Synta (Inst)
Patents, Royalties, Other Intellectual Property - Myriad Genetics (royalties)
Travel, Accommodations, Expenses - Novartis
 
Yelena Novik
Honoraria - Celgene
 
James L. Speyer
No Relationships to Disclose
 
Ruth Oratz
No Relationships to Disclose
 
Marleen Iva Meyers
No Relationships to Disclose
 
Deborah M. Axelrod
Speakers' Bureau - Genomic Health
 
Rebecca Hogan
No Relationships to Disclose
 
Sandra Mendoza
No Relationships to Disclose
 
Judith D. Goldberg
Consulting or Advisory Role - ARMO BioSciences; Cascadian Therapeutics; Merck; Oncobiologics
 
Franco Muggia
Consulting or Advisory Role - Genentech/Roche; Merck
 
Sylvia Adams
Research Funding - Genentech; Merck